medigraphic.com
ISSN 2594-1518 (Electronic)
ISSN 1405-0099 (Print)

2010, Number 2

<< Back Next >>

Cir Gen 2010; 32 (2)

GIST tumors. Clinical, epidemiological, histopathological, and histochemical profile in a third level health care hospital

Vázquez-Guerrero AL, Medina-Morín JL, Pińa-Osuna AK, Vázquez-Reta JA, Vázquez-Guerrero A, Méndez-Pérez JÁ, Alonso-Rosales JC

Language: Spanish
References: 20
Page: 100-105
PDF size: 204.44 Kb.


ABSTRACT

Objective: To determine the clinical-epidemiological, histopathological and immunohistochemical profile of gastrointestinal stromal tumors (GIST).
Setting: High Specialty Medical Unit No. 25 of the Mexican Institute of Social Security (IMSS, for its initials in Spanish), in the city of Monterrey, NL, Mexico. Design. Survey.
Statistical analysis: Descriptive statistics, chi square, and Kolmogorov-Smirnov (KS) normality test.
Patients and methods: Adults with a histological diagnosis of GIST, confirmed through immunohistochemistry by the presence of C-kit (CD117), CD34, actin desmin, and S100, studied from 2005 to 2008. We recorded the variables that integrate the clinical-epidemiological, histopathological, immunohistochemical profile, as well as the risk of aggressiveness and malignant potential according to the Fletcher and Butcher classifications.
Results: There were 13 women (54%) and 11 men, median age of 57 years (range, 30 to 85), whose main clinical presentations were bleeding of the lower digestive tract and a palpable mass in seven (29.2%) patients for each of them. Performed surgery was intestinal resection in 10 (41.7%); location, 37% in the stomach; oncological staging corresponded to regional dissemination in 15 (62.5%); main cellular type was fusocellular in 12 (50%). Immunohistochemically positive in 21 (87.5%) to CD 117, 14 (58.3%), to CD 117 plus CD were 34. High degree of aggresivity was found in 17 (70.8%).
Conclusion: The behavior of the sample seems to be aggressive and helps to describe the conformation of the different profiles of the population of patients with GIST.


REFERENCES

  1. Azcoitia MF. Tumores del estroma gastrointestinal: definición, generalidades y epidemiología. Cir Gen 2008; 30: S5-S10.

  2. Clark MA, Fisher C, Judson I, Thomas JM. Medical progress: Soft-tissue sarcomas in adults. N Engl J Med 2005; 353: 701-11.

  3. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507-19.

  4. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: An analysis of 1,458 cases from 1992 to 2002. Am J Gastroenterol 2005; 100: 162-8.

  5. Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. A population-based study in western sweden. Cancer 2005; 103: 821-29.

  6. Torihashi S, Horisawa M, Watanabe Y. c-Kit immunoreactive interstitial cells in the human gastrointestinal tract. J Auton Nerv Syst 1999; 75: 38-50.

  7. Krause DS, Van Etten RA. Mechanisms of disease: Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-187.

  8. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain of function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.

  9. Azcoitia-Moraila F. Tumores del estroma gastrointestinal. Una visión del presente hacia el futuro. Cir Gen 2007; 29: 7-9.

  10. Heinrich M, Corless C, Demetri G, Blanke C, Von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour. J Clin Oncol 2003; 21: 4342–9.

  11. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Int J Surg Pathol 2002; 10: 81-9.

  12. Kipps TJ. The cluster of differentiation antigens. In Williams Hematology. 7th edition New York. McGraw-Hill 2005: 141.

  13. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117(KIT). Mod Pathol 2000; 13: 1134-42.

  14. Alvarado CI, Vázquez G, Sierra Santiesteban FI, Hernández-Hernández DM, Zavala-Pompa A. A clinicopathologic study of 275 cases of gastrointestinal stromal tumors: the experience at 3 large medical centers in Mexico. Ann Diagn Pathol 2007; 11: 39-45.

  15. Lehnert T. Gastrointestinal sarcoma (GIST)- a review of surgical management. Ann Chir Gynaecol 1998; 87: 297–305.

  16. Bucher P, Taylor S, Villiger P, Morel P, Brundler M. For small intestinal stromal tumours are there any prognostic factors. Am J Surg 2004; 187: 761-6.

  17. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692–703.

  18. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010; 8: S1-41; quiz S42-4.

  19. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumour: a randomized, double-blind, placebo-controlled trial. Lancet 2009; 373(9669): 1097-104.

  20. Blay JY. New paradigms in gastrointestinal stromal tumour management. Ann Oncol 2009; 20 Supl1: i18-24.




2020     |     www.medigraphic.com